ABSTRACT
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely fresh approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQs), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed, then answered FAQs, and finalized topics with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. This second guideline in the series focuses on invasive aspergillosis, a potentially life-threatening infection in the peri-HCT period. The relevant risk factors, diagnostic considerations, and prophylaxis and treatment approaches are reviewed.
Subject(s)
Aspergillosis , Hematopoietic Stem Cell Transplantation , Invasive Fungal Infections , Adult , Aspergillosis/diagnosis , Cell- and Tissue-Based Therapy , Child , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Transplant Recipients , United StatesABSTRACT
Timely diagnosis and treatment of invasive mould disease is challenging in severely immunocompromised patients, particularly for patients who develop breakthrough infections while on antifungal prophylaxis. Currently, there are no high-quality data on how to best diagnose and treat these infections. Many essential decisions affecting the management of breakthrough mould disease are made before a definitive diagnosis is established. In this scenario, sound management reasoning often favours the use of combination antifungal therapy, especially when antifungal resistance, suspicion of undetected sites of infection or pharmacokinetic/pharmacodynamic limitations at the site of infection are likely. In these scenarios, pre-emptive use of antifungal combination therapy with frequent re-evaluation with an aim of de-escalation could be justified for many high-risk patients.
Subject(s)
Antifungal Agents , Hematologic Neoplasms , Antifungal Agents/therapeutic use , Drug Resistance, Fungal , Evidence-Based Medicine , Fungi , Hematologic Neoplasms/complications , Hematologic Neoplasms/drug therapy , Humans , Immunocompromised HostABSTRACT
There is a paucity of studies on the yield of Gomori-methenamine-silver (GMS) staining in bronchoalveolar lavage (BAL) fluid cytology and its comparison with fluorescent dye staining for the diagnosis of invasive pulmonary aspergillosis (IPA) in patients with hematologic malignancies. To that end, we analyzed the yield of direct fungal visualization in BAL fluid cytology with GMS staining, in a series of culture-positive IPA cases in 67 patients with hematologic malignancies, and we compared the results with those of direct examination with calcofluor white staining and BAL fluid galactomannan assays, when available. GMS staining in BAL fluid cytology was positive in 42% of the 67 cases and revealed coinfections in 7 cases. In contrast, only 2/67 (3.6%) BAL fluid samples were positive in direct smears stained with the fluorescent dye calcofluor white. Positive GMS staining results were significantly more frequent in IPA cases with cavitary lesions and IPA cases caused by >1 Aspergillus species, but the proportions of positive cytology results among Aspergillus species were not different.
Subject(s)
Aspergillus/isolation & purification , Bronchoalveolar Lavage Fluid/microbiology , Hematologic Neoplasms/complications , Invasive Pulmonary Aspergillosis/diagnosis , Staining and Labeling/methods , Adult , Aspergillus/metabolism , Fluorescent Dyes/metabolism , Hematologic Neoplasms/microbiology , Humans , Invasive Pulmonary Aspergillosis/complications , Invasive Pulmonary Aspergillosis/pathology , Methenamine/metabolism , Retrospective Studies , Sensitivity and SpecificityABSTRACT
OBJECTIVES: A prospective international multicentre surveillance study was conducted to investigate the prevalence and amphotericin B susceptibility of Aspergillus terreus species complex infections. METHODS: A total of 370 cases from 21 countries were evaluated. RESULTS: The overall prevalence of A. terreus species complex among the investigated patients with mould-positive cultures was 5.2% (370/7116). Amphotericin B MICs ranged from 0.125 to 32 mg/L, (median 8 mg/L). CONCLUSIONS: Aspergillus terreus species complex infections cause a wide spectrum of aspergillosis and the majority of cryptic species display high amphotericin B MICs.
Subject(s)
Aspergillosis/epidemiology , Aspergillosis/microbiology , Aspergillus/classification , Aspergillus/isolation & purification , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Aspergillus/drug effects , Epidemiological Monitoring , Europe/epidemiology , Humans , Microbial Sensitivity Tests , Prevalence , Prospective StudiesABSTRACT
OBJECTIVES: We sought to determine the frequency at which patients with elevated voriconazole (VRC) levels but no clinically evident central nervous system (CNS) toxicity subsequently develop CNS toxicity. METHODS: We retrospectively reviewed the records of adult patients with haematolologic malignancy who had a VRC serum level >5.5 µg/mL at MD Anderson Cancer Center (January 2010 to December 2015). Patients with any documented CNS toxicity at the time the VRC level was obtained or patients whose VRC was discontinued as a response to high VRC level were excluded. Neurologic status was assessed using standard grading scales. Demographic and clinical characteristics, including potentially interacting medications, were correlated with the development of toxicity. RESULTS: We identified 320 such patients (mean age, 57 ± 15 years; 202 male (63%)). Subsequent CNS toxicity was documented in only 16 patients (5%). The most common CNS toxicities were visual disturbances (9/16, 56%), depressed consciousness (5/16, 31%) and cognitive disturbance (4/16, 19%). Patients with CNS toxicity tended to be older than those without (64 ± 8 vs 57 ± 15 y, p 0.08). The use of one or more neurotoxic drugs was common in patients with subsequent CNS toxicity (14/16, 88%). Reduction of VRC dose associated with the high VRC level did not correlate with less subsequent CNS toxicity. CONCLUSIONS: Development of subsequent CNS toxicity is uncommon in haematolologic malignancy patients with elevated VRC levels who had no evidence of toxicity at the time the level was obtained. Automatic reduction of VRC dose out of concern for impending CNS toxicity might not be warranted.
Subject(s)
Antifungal Agents/toxicity , Central Nervous System/drug effects , Hematologic Neoplasms/blood , Voriconazole/toxicity , Adult , Age Factors , Aged , Antifungal Agents/blood , Cognitive Dysfunction/chemically induced , Consciousness Disorders/chemically induced , Female , Humans , Male , Middle Aged , Retrospective Studies , Vision Disorders/chemically induced , Voriconazole/bloodSubject(s)
Hematopoietic Stem Cell Transplantation , Leukemia , Myelodysplastic Syndromes , Thorax/diagnostic imaging , Tomography, X-Ray Computed , Adolescent , Adult , Aged , Allografts , Aspergillus fumigatus , Female , Humans , Leukemia/diagnostic imaging , Leukemia/mortality , Leukemia/therapy , Male , Middle Aged , Mycobacterium avium Complex , Mycobacterium avium-intracellulare Infection/diagnostic imaging , Mycobacterium avium-intracellulare Infection/mortality , Myelodysplastic Syndromes/diagnostic imaging , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/therapy , Pneumonia/diagnostic imaging , Pneumonia/mortality , Pneumonia/therapy , Pulmonary Aspergillosis/diagnostic imaging , Pulmonary Aspergillosis/mortality , Pulmonary Aspergillosis/therapy , Retrospective StudiesABSTRACT
Hematopoietic stem cell transplantation (HSCT) can be lifesaving for some of the deadliest hematologic diseases. However, immunosuppression, polypharmacy and risk of infectious complications associated with HSCT can increase morbidity and mortality for recipients. Incidence of acute kidney injury (AKI) after HSCT can be as high as 70%, and concomitant infection can be a therapeutic challenge for oncologists, nephrologists and infectious disease specialists. We illustrate this challenge in the case of a 31-year-old man with acute lymphoblastic leukemia who underwent a double cord HSCT complicated by GvHD, systemic cryptococcal and BK virus infections and AKI. Kidney biopsy showed round to cup-shaped organisms with occasional budding, consistent with Cryptococcus and thrombotic microangiopathy. We discuss our findings and a literature review of disseminated cryptococcal infection with renal involvement after HSCT.
Subject(s)
Acute Kidney Injury/etiology , Cryptococcosis/transmission , Hematopoietic Stem Cell Transplantation/adverse effects , Acute Kidney Injury/microbiology , Adult , Hematopoietic Stem Cell Transplantation/methods , Humans , Male , Thrombotic Microangiopathies/etiology , Transplantation, HomologousABSTRACT
In view of the poor outcomes associated with mucormycosis in patients with haematologic malignancies (HM) and haematopoietic cell transplant recipients, antifungal combinations are frequently used, yet the value of such strategy remains unclear. We reviewed the records of HM patients treated for mucormycosis from 1994 to 2014. The primary outcome was 6-week mortality after treatment initiation. Of the 106 patients identified, 44% received monotherapy and 56% received combination treatment as initial therapy. Six-week mortality was associated with disseminated mucormycosis (p 0.018), active malignancy (p <0.01), higher Acute Physiology and Chronic Health Evaluation (APACHE) II scores (p <0.001), neutropenia (p 0.049), lymphopenia (p 0.0003) and intensive care unit (ICU) admission at diagnosis (p 0.0001). Survivors were more likely to have localized mucormycosis (p <0.01) and to receive hyperbaric oxygen therapy (p 0.02). There were no differences in mortality between monotherapy and combination treatment groups (43% vs. 41%; p 0.85). In multivariate analysis, lymphopenia (odds ratio (OR), 5.5; 95% confidence interval (CI), 1.9-15.9; p 0.002) and ICU admission at diagnosis (OR, 8.2; 95% CI, 2.3-29.2; p 0.001) were associated with increased mortality. Localized mucormycosis was associated with better outcome (OR, 0.06; 95% CI, 0.01-0.6; p 0.019). Initial combination treatment had no impact on mortality, even after propensity score adjustment (OR, 0.8; 95% CI, 0.3-2.4; p 0.69). A weighted mortality risk score was then calculated for each patient based on the factors independently associated with mortality and baseline APACHE II score. In the low-risk group (n = 49), 13% of monotherapy versus 15% of combination therapy patients died within 6 weeks (p >0.99). In the high-risk group (n = 57), 71% of monotherapy versus 61% of combination therapy patients died within 6 weeks (p 0.42). With the current status of mucormycosis diagnosis, there was no difference in mortality in HM patients, whether they received monotherapy or combination treatment as initial therapy. Earlier diagnosis and immune reconstitution are unmet needs to affect outcomes.
Subject(s)
Antifungal Agents/therapeutic use , Hematologic Neoplasms/complications , Mucormycosis/drug therapy , Mucormycosis/etiology , Adolescent , Adult , Aged , Antifungal Agents/administration & dosage , Drug Therapy, Combination , Female , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Incidence , Male , Middle Aged , Mortality , Mucormycosis/diagnosis , Mucormycosis/mortality , Propensity Score , Retrospective Studies , Severity of Illness Index , Treatment Outcome , Young AdultABSTRACT
Nephropathy due to BK virus (BKV) infection is an evolving challenge in patients undergoing hematopoietic stem cell transplantation (HSCT). We hypothesized that BKV infection was a marker of kidney function decline and a poor prognostic factor in HSCT recipients who experience this complication. In this retrospective study, we analyzed all patients who underwent their first allogeneic HSCT at our institution between 2004 and 2012. We evaluated the incidence of persistent kidney function decline, which was defined as a confirmed reduction in estimated glomerular filtration rate of at least 25% from baseline using the Chronic Kidney Disease Epidemiology equation. Cox proportional hazard regression was used to model the cause-specific hazard of kidney function decline, and the Fine-Gray method was used to account for the competing risks of death. Among 2477 recipients of a first allogeneic HSCT, BK viruria was detected in 25% (n = 629) and kidney function decline in 944 (38.1%). On multivariate analysis, after adjusting for age, sex, acute graft-versus-host disease (GVHD), chronic GVHD, preparative conditioning regimen, and graft source, BK viruria remained a significant risk factor for kidney function decline (p < 0.001). In addition, patients with BKV infection and kidney function decline experienced worse overall survival. After allogeneic HSCT, BKV infection was strongly and independently associated with subsequent kidney function decline and worse patient survival after HSCT.
Subject(s)
BK Virus/pathogenicity , Graft vs Host Disease/mortality , Hematologic Diseases/mortality , Hematopoietic Stem Cell Transplantation/adverse effects , Kidney Diseases/mortality , Polyomavirus Infections/mortality , Tumor Virus Infections/mortality , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft vs Host Disease/etiology , Hematologic Diseases/complications , Hematologic Diseases/therapy , Humans , Infant , Infant, Newborn , Kidney Diseases/virology , Kidney Function Tests , Male , Middle Aged , Polyomavirus Infections/virology , Prognosis , Retrospective Studies , Risk Factors , Survival Rate , Transplantation, Homologous , Tumor Virus Infections/virology , Young AdultABSTRACT
OBJECTIVES: Invasive mould sinusitis (IMS) is a severe infection in patients with haematological malignancies. Because of a paucity of contemporaneous data about IMS, we sought to evaluate clinical aspects and outcome of IMS in these patients. METHODS: The records of adult haematological malignancy patients with proven or probable IMS over a 10 year period were reviewed retrospectively. RESULTS: We identified 44 patients with IMS. Mucorales were isolated in 13 (35.1%) patients and Fusarium and Aspergillus were isolated in 9 (24.3%) patients each. Patients with IMS owing to Mucorales were more likely to have a history of diabetes mellitus (P = 0.003) and high-dose corticosteroid use (P = 0.03). Thirty-five (80%) patients received antifungal combinations and 36 (82%) underwent surgical debridement. The 12 week IMS-attributable mortality was 36.4% (16 patients). A relapsed and/or refractory haematological malignancy was an independent risk factor for 6 week IMS-attributable (P = 0.038), 12 week all-cause (P = 0.005) and 12 week IMS-attributable (P = 0.0015) mortality. Neutrophil count <100/µL and lymphocyte count <200/µL were associated with increased 12 week IMS-attributable and 6 week all-cause mortality, respectively (P = 0.044 and 0.013). IMS due to Aspergillus was an independent risk factor for both 12 week all-cause (P = 0.011) and IMS-attributable (P = 0.026) mortality. Initial antifungal therapy with a triazole-containing regimen was associated with decreased 6 week all-cause (P = 0.032) and IMS-attributable (P = 0.038) mortality. Surgery was not an independent factor for improved outcome. CONCLUSIONS: Despite combined medical and surgical therapy, IMS had high mortality. Mortality risk factors were relapsed and/or refractory malignancy, cytopenia and Aspergillus infection in this study.
Subject(s)
Hematologic Neoplasms/complications , Hematologic Neoplasms/epidemiology , Mycoses/epidemiology , Mycoses/etiology , Sinusitis/epidemiology , Sinusitis/etiology , Academic Medical Centers , Adult , Aged , Antibiotic Prophylaxis , Antifungal Agents/therapeutic use , Cause of Death , Cross Infection , Female , Hematologic Neoplasms/diagnosis , Humans , Incidence , Magnetic Resonance Imaging , Male , Middle Aged , Mycoses/diagnosis , Mycoses/drug therapy , Mycoses/prevention & control , Outcome Assessment, Health Care , Retrospective Studies , Sinusitis/diagnosis , Sinusitis/drug therapy , Sinusitis/prevention & control , Texas/epidemiology , Tomography, X-Ray ComputedABSTRACT
Candida biofilms play an important role in infections associated with medical devices and are resistant to antifungals. We hypothesized that the echinocandin micafungin (MICA) exerts an enhanced antifungal activity against caspofungin (CAS)-susceptible (CAS-S) and CAS-non-susceptible (CAS-NS) Candida albicans and Candida parapsilosis which is at least in part through apoptosis, even in the biofilm environment. Apoptosis was characterized by detecting reactive oxygen species (ROS) accumulation, depolarization of mitochondrial membrane potential (MMP), DNA fragmentation, lack of plasma membrane integrity, and metacaspase activation following exposure of Candida biofilm to MICA for 3h at 37°C in RPMI 1640 medium. The minimum inhibitory concentration was higher for CAS (2.0-16.0 µg/mL) than for MICA (1.0-8.0 µg/mL) for Candida biofilms. Elevated intracellular ROS levels and depolarization of MMP was evident in CAS-S C. albicans (3.0-4.2 fold) and C. parapsilosis (4.8-5.4 fold) biofilms compared with CAS-NS (1.2 fold) after exposure to MICA (0.25x-1xMIC). Elevated intracellular ROS levels and depolarization of MMP was evident in CAS-S C. albicans (3.0-4.2 fold) and C. parapsilosis (4.8-5.4 fold) biofilms compared with CAS-NS (1.2 fold) after exposure to MICA (0.25x-1xMIC). Finally higher ß-1, 3 glucan levels were seen in sessile cells compared to planktonic cells, especially in CAS-NS strains. MICA treatment might induce a metacaspase-dependent apoptotic process in biofilms of both CAS-S C. albicans and C. parapsilosis, and to some degree in CAS-NS strains.
Subject(s)
Antifungal Agents/pharmacology , Apoptosis/drug effects , Biofilms/drug effects , Candida albicans/drug effects , Candida/drug effects , Caspases/metabolism , Echinocandins/pharmacology , Lipopeptides/pharmacology , Biofilms/growth & development , Candida/isolation & purification , Candida/physiology , Candida/ultrastructure , Candida albicans/physiology , Candida albicans/ultrastructure , Caspofungin , DNA Fragmentation , Drug Resistance, Fungal , Membrane Potential, Mitochondrial/drug effects , Micafungin , Microbial Sensitivity Tests , Reactive Oxygen Species/metabolismABSTRACT
Glucocorticoid (GC) use is a common risk factor for invasive fungal infections. This is attributed to the complex dysregulation of immunity caused by GCs. However, studies have demonstrated increased growth with GC exposure for some molds, such as Aspergillus fumigatus and Exserohilum rostratum. No such data exist for Mucorales. Therefore, we investigated the influence of GC exposure on the growth of Rhizopus arrhizus (syn. R. oryzae) in different culture media and in different atmospheres. We measured continuous spore growth using spectrophotometry and biomass variations using XTT assay. We did not observe enhanced growth or biomass variation with any of the GCs regardless of the medium or conditions. These results support the existence of fungus-specific differences in the effect of GCs on fungal biology.
Subject(s)
Biomass , Glucocorticoids/pharmacology , Rhizopus/drug effects , Rhizopus/growth & development , Culture Media/chemistry , Dexamethasone/pharmacology , Hydrocortisone/pharmacology , Mucormycosis/microbiology , Prednisone/analogs & derivatives , Prednisone/pharmacology , Rhizopus/metabolism , Spectrophotometry , Spores, Fungal/drug effects , Spores, Fungal/growth & developmentABSTRACT
Invasive fungal infections (IFIs) are being increasingly recognized in solid organ transplant (SOT) recipients, and delayed diagnosis can lead to graft loss and death. Therefore, there is a low threshold for prophylaxis and early initiation of empiric antifungal treatment, in this patient population. Meanwhile, the increasing consumption of antifungals is associated with high cost, medication toxicities and the emergence of resistance in Candida species, all of which call for rational use of antifungal agents. The implementation of fungal biomarkers, molecular diagnostic methods and direct detection of volatile fungal metabolites in breath samples could lead to faster diagnosis, early appropriate treatment and improved clinical outcomes, but also aid in the de-escalation of antifungal treatment. Those novel diagnostic modalities need to be validated specifically in SOT recipients. Infectious diseases consultation can contribute to optimization of care through prompt initiation and appropriate modification of antifungal treatment, management of medication toxicities and drug-drug interactions, as well as source control. In this review, we conceptually summarize recent advances in the diagnosis and management of IFI in SOT recipients, and highlight the importance of early diagnostic tools and good stewardship of antifungal drugs.
Subject(s)
Mycoses/complications , Transplantation/adverse effects , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Drug Resistance, Microbial , Humans , Microbial Sensitivity Tests , Mycoses/epidemiology , Transplant RecipientsABSTRACT
In patients with malignancies, Candida glabrata is one of the most frequent non-albicans Candida clinical isolates. As antifungal resistance in C. glabrata is common, we investigated the relationship between early appropriate antifungal treatment, infectious disease (ID) consultation and mortality in a contemporary cohort of cancer patients with C. glabrata fungaemia. We included patients with at least one C. glabrata-positive blood culture and symptoms or signs of infection seen at the MD Anderson Cancer Center between March 2005 and September 2013. In vitro susceptibility to antifungals was defined according to the 2010 CLSI clinical breakpoints. One-hundred and forty-six episodes of candidaemia were studied. Thirty isolates (20.5%) had fluconazole MIC ≥ 64 mg/L and 15 (10.3%) were caspofungin-resistant. Early (within 48 h after blood culture collection) initiation of appropriate antifungal treatment (hazard ratio 0.374, p 0.003) and early ID consultation (hazard ratio 0.421, p 0.004) were associated with decreased mortality, after adjustment for significant confounders. Thirty-two of 58 patients (55.2%) followed by ID were on appropriate antifungals within 48 h, compared with 16/88 patients (18.2%) who were not followed by ID an ID specialist (p <0.001). The median time-to-reporting of blood culture positivity for yeast was 71 h. Delayed time-to-reporting was associated with increased 28-day all-cause mortality (log-rank p 0.023). The benefits from early initiation of appropriate antifungal treatment and ID consultation were more prominent in patients with non-catheter-related candidaemia. In conclusion, in cancer patients with C. glabrata fungaemia, early ID consultation may lead to timely initiation of appropriate treatment and improved clinical outcomes.
Subject(s)
Candida glabrata , Candidemia , Neoplasms/complications , Neoplasms/mortality , Referral and Consultation/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Antifungal Agents/therapeutic use , Candidemia/complications , Candidemia/drug therapy , Candidemia/epidemiology , Catheter-Related Infections , Child , Female , Humans , Infectious Disease Medicine , Male , Middle Aged , Retrospective Studies , Time-to-Treatment/statistics & numerical data , Young AdultABSTRACT
The objective of this investigation was to review the clinical manifestations, management, and outcome of osteoarticular infections caused by dimorphic fungi. We exhaustively reviewed reports of bone and joint infections caused by dimorphic fungi published between 1970 and 2012. Underlying conditions, microbiological features, histological characteristics, clinical manifestations, antifungal therapy, and outcome were analyzed in 222 evaluable cases. Among 222 proven cases (median age 41 years [interquartile range (IQR) 26-57]), 73 % had no predisposing condition. Histopathology performed in 128 (57 %) cases and culture in 170 confirmed diagnosis in 63 % and 98 % of the cases, respectively. Diagnosis was obtained from an extra-osteoarticular site in 16 cases. The median diagnostic time was 175 days (IQR 60-365). Sporothrix schenckii was the most frequent pathogen (n = 84), followed by Coccidioides immitis (n = 47), Blastomyces dermatitidis (n = 44), Histoplasma capsulatum (n = 18), Paracoccidioides brasiliensis (n = 16), and Penicillium marneffei (n = 13). Arthritis occurred in 87 (58 %) cases and osteomyelitis in 64 (42 %), including 19 vertebral osteomyelitis. Dissemination was reported in 123 (55 %) cases. Systemic antifungal agents were used in 216 (97 %) patients and in combination with surgery in 129 (60 %). Following the Infectious Diseases Society of America (IDSA) guidelines, a successful initial medical strategy was observed in 97/116 (84 %) evaluable cases. The overall mortality was 6 %, and was highest for P. marneffei (38.5 %). This study demonstrates that dimorphic osteoarticular infections have distinctive clinical presentations, occur predominantly in apparently immunocompetent patients, develop often during disseminated disease, and may require surgical intervention.
Subject(s)
Bone Diseases, Infectious/microbiology , Mitosporic Fungi/isolation & purification , Mycoses/microbiology , Adolescent , Adult , Antifungal Agents/therapeutic use , Bone Diseases, Infectious/pathology , Bone Diseases, Infectious/therapy , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Mycoses/pathology , Mycoses/therapy , Young AdultABSTRACT
The calcineurin pathway regulates antifungal drug resistance and the virulence of several major human-pathogenic fungi, including the recalcitrant Mucorales. We hypothesized that the fungistatic triazoles posaconazole (PCZ) and itraconazole (ICZ) become fungicidal in the setting of the calcineurin inhibitor tacrolimus (TCR) and that such an effect is mediated through apoptosis. Fungicidal activity and apoptosis were studied using standard microbiological techniques and hyphal metabolic and vital dye reduction assays at 37°C in RPMI 1640. Apoptosis was characterized by detecting intracellular Ca(2+), phosphatidylserine (PS) externalization, DNA fragmentation, plasma membrane integrity, chromatin condensation, reactive oxygen species (ROS) generation, caspase-like activity, ATP, and cytochrome c release. MICs for PCZ and ICZ alone were significantly higher (8 to 128 µg/ml) than those of PCZ or ICZ plus TCR (0.25 to 4 µg/ml) for Rhizopus oryzae, Cunninghamella bertholletiae, and Mucor circinelloides. Both PCZ and ICZ in combination with TCR became fungicidal, and their activity was mediated through increased apoptotic cell death of R. oryzae (10 to 50%), C. bertholletiae (5 to 50%), and M. circinelloides (5 to 55%) germlings, with morphological apoptotic changes characterized by externalization of PS, nuclear condensation, and DNA fragmentation. Moreover, activation of the caspase-like activity was correlated with cell death induced by TCR plus PCZ or ICZ. These changes correlated with elevated intracellular Ca(2+) and ROS levels and disturbance of mitochondrial potential. We found that PCZ or ICZ in combination with TCR renders Mucorales sensitive to triazoles via apoptotic death. These observations could serve as a new paradigm for the development of new therapeutic strategies.
Subject(s)
Antifungal Agents/pharmacology , Apoptosis/drug effects , Itraconazole/pharmacology , Mucorales/drug effects , Tacrolimus/pharmacology , Triazoles/pharmacology , Calcineurin Inhibitors , Dose-Response Relationship, Drug , Mucorales/physiologySubject(s)
Antibiotic Prophylaxis , Antifungal Agents/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia/therapy , Mycoses/complications , Triazoles/therapeutic use , Adolescent , Adult , Aged , Antibiotic Prophylaxis/adverse effects , Antifungal Agents/adverse effects , Child , Cohort Studies , Drug Therapy, Combination/adverse effects , Female , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , Humans , Leukemia/complications , Male , Middle Aged , Mycoses/drug therapy , Mycoses/mortality , Mycoses/prevention & control , Retrospective Studies , Secondary Prevention , Transplantation, Homologous , Triazoles/adverse effects , Young AdultABSTRACT
The emergence of fluconazole-resistant Candida (FRC) is worrisome, but little is known about susceptibility patterns in different nosocomial settings. We prospectively analysed Candida bloodstream isolates in 18 medical centres in Israel (six tertiary-care and 12 community hospitals). The study included 444 episodes of candidaemia (450 patient-specific isolates, 8.5% fluconazole-resistant). Institutional FRC bloodstream infection rates correlated with annual inpatient days, and were strongly associated with the presence and activity of haematology/oncology services. Infection with Candida krusei and fluconazole-resistant Candida glabrata occurred exclusively in hospitals with >600 beds. These findings suggest that empirical antifungal strategies should be tailored to the nosocomial setting.
Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Candidemia/epidemiology , Cross Infection/epidemiology , Drug Resistance, Fungal , Fluconazole/pharmacology , Adult , Aged , Candida/isolation & purification , Candida glabrata , Female , Hospitals , Humans , Israel/epidemiology , Male , Middle Aged , Prevalence , Prospective StudiesABSTRACT
We evaluated the diagnostic yield of open-lung biopsies (OLBs) in a large tertiary cancer center to determine the role of infectious diseases as causes of undiagnosed pulmonary lesions. All consecutive adult patients with either single or multiple pulmonary nodules or masses who underwent a diagnostic OLB over a period of 10 years (1998-2007) were retrospectively identified. Their risk factors for malignancy and clinical and radiological characteristics were reviewed, and their postoperative complications were assessed. We evaluated 155 patients with a median age of 57 years (range, 19-83 years). We identified infectious etiologies in 29 patients (19 %). The most common diagnosis in this group was histoplasmosis (12 [41 %]), followed by nontuberculous mycobacterial infection (7 [24 %]) and aspergillosis (4 [14 %]). The majority of the 126 remaining patients had nonmalignant diagnoses, the most prevalent being nonspecific granuloma (26 %), whereas only 17 % had malignant diagnoses. We observed no significant differences among the patients with infectious, malignant, or both noninfectious and nonmalignant final diagnoses regarding their demographic, laboratory, and clinical characteristics. Six percent of the patients had at least one post-OLB complication, and the post-OLB mortality rate was 1 %. OLB is a safe diagnostic procedure which frequently identifies a wide variety of infectious and inflammatory diseases.